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Percutaneous transluminal coronary angioplasty was per- 
formed as primary therapy in 215 consecutive patients 
(aged 56 + 11 years, 75% male) with acute myoeardial 
infarction and single vessel coronary artery disease. Wide 
patency of the infarct-related artery was restored in 212 
patients (99%). Complications consisted of one urgent 
coronary bypass operation (0.5%); there were no proce- 
dural deaths. A recurrent ischemic event before discharge 
occurred in eight patients (4%). The in-hospital mortality 
rate was 1%; five of six patients presenting with cardiogenic 
shock were alive at discharge. 
In 126 patients in whom predischarge angiography was 
performed, the ejection fraction improved from 55 f 12% 
to 61 + 12% (p < 0.005) and increased by ~5% units in 66 
patients (52%). Regional wall motion improved in 60 
patients (48%). By multivariate analysis, a depressed initial 
ejection fraction, a limited increase in serum creatine 
kinase, young age and sustained patency of the infarct- 
related artery were found to be independent predictors of 
improvement in left ventricular function. 
Recent studies (l-9) have established that early reperfusion 
in acute myocardial infarction can limit infarct size and 
decrease mortality. After myocardial infarction, the in- 
hospital survival rate and late prognosis are largely deter- 
mined by left ventricular function (lo-13), residual myocar- 
dial ischemia (14-16) and the number of diseased epicardial 
coronary arteries (11-14). Angiographic studies (11-14) have 
revealed a 30% to 58% incidence rate of single vessel 
coronary artery disease in survivors of myocardial infarc- 
tion. Although mortality and recurrent infarction rates are 
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Follow-up data were available in 214 patients (99.5%) 
at a mean interval of 35 months. The actuarial 3 year 
cardiac survival rate was 92%. By multivariate analysis, 
only the baseline ejection fraction correlated with long-term 
cardiac survival. Nine patients (4%) sustained a late non- 
fatal myocardial infarction, and 11 patients (5%) under- 
went subsequent coronary bypass surgery. At late follow- 
up study, 149 (77%) of 194 patients alive were free of 
angina. 
In summary, in patients with acute myocardial infarc- 
tion and single vessel disease, coronary angioplasty without 
prior thrombolytic therapy can be performed with a high 
success rate and few procedural complications. After direct 
angioplasty, regional wall motion and global ejection frac- 
tion improve in 50% of patients, especially in those with 
depressed initial left ventricular function. This approach 
results in an excellent early and late event-free survival. 
(J Am Co11 Cardiol1990;15:534-43) 
low after uncomplicated infarction in patients with single 
vessel disease, inducible ischemia remains in a significant 
proportion of patients, and over half may develop angina 
that frequently limits activity and requires hospitalization 
(15). The optimal therapy for patients with single vessel 
disease presenting with acute myocardial infarction is un- 
known. Studies involving reperfusion have not specifically 
addressed the factors affecting the short- and long-term 
prognosis, ischemic event rate and determinants of myocar- 
dial salvage in patients with single vessel disease after 
myocardial infarction. 
At the Mid America Heart Institute, our approach to the 
management of the patient in the early stages of acute 
myocardial infarction has been immediate coronary arteri- 
ography followed by direct coronary angioplasty without the 
use of prior thrombolytic therapy. This report describes the 
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short-term outcome and long-term prognosis after applica- 
tion of direct angioplasty in patients with acute myocardial 
infarction resulting from single vessel disease, and examines 
the clinical and angiographic factors influencing prognosis 
and myocardial salvage in this cohort of patients. 
Methods 
Study patients. Between March 12, 1981 and March 30, 
1988,500 consecutive patients with acute myocardial infarc- 
tion were treated with direct coronary angioplasty without 
prior thrombolytic therapy; 215 patients (43%) had single 
vessel coronary artery disease and form the basis of this 
report. Patients were included if they presented with persist- 
ent chest discomfort of <24 h duration and unresponsive to 
sublingual nitroglycerin, along with electrocardiographic 
(ECG) evidence of acute myocardial injury (21 mm ST 
segment elevation in two or more contiguous leads) and the 
ability to give informed consent. No patient was excluded 
for advanced age, prior myocardial infarction or coronary 
bypass surgery, clinical heart failure, left ventricular 
dysfunction or cardiogenic shock. No patient received 
thrombolytic therapy before angioplasty. All patients gave 
informed consent for the angioplasty procedure and subse- 
quent studies. 
Angioplasty protocol. The catheterization team was mo- 
bilized immediately after patient consent. In general, the 
procedure was initiated within 30 to 60 min after arrival of 
the patient in the emergency room. 
Unless contraindicated, routine premeditations consisted 
of aspirin (325 mg orally), isosorbide dinitrate (5 mg sublin- 
gually), lidocaine (75 mg intravenously), verapamil (5 mg 
intravenously), dextran (500 cc intravenously) and heparin 
(10,000 U intravenously, followed by 5,000 U/h intrave- 
nously during the angioplasty procedure). 
In patients with cardiogenic shock (systolic blood pres- 
sure ~80 mm Hg with clinical evidence of systemic hypo- 
perfusion and left ventricular ejection fraction <30%), an 
intraaortic balloon pump was placed before angiography, 
and pressor support was utilized as indicated. In general, left 
ventriculography in the 30” right anterior oblique projection 
was performed first, followed by visualization of the nonin- 
farct-related arteries and finally the infarct-related artery. A 
stenosis was considered significant if there was >50% ob- 
struction in any view. 
Coronary angioplasty was performed utilizing standard 
over the wire balloon catheters, as previously described (17). 
Typically, three to five inflations lasting 45 to 120 s were 
performed across the lesion using pressure sufficient to 
achieve full balloon expansion. The angioplasty procedure 
was considered successful if the residual stenosis was ~40% 
obstructive in all views, and no major procedural complica- 
tions occurred (death or urgent bypass surgery). 
Postangioplasty protocol. Heparin was continued for 48 h 
routinely. All patients were maintained on aspirin (325 mg 
three times daily), dipyridamole (75 mg three times daily) 
and an oral calcium channel blocker. Cardiac enzymes were 
obtained every 8 to 12 h for at least 48 h. Any patient 
displaying signs of recurrent ischemia (exertional or rest 
angina, reinfarction, cardiac arrest or a positive submaximal 
exercise test) at any time before discharge underwent repeat 
catheterization. In addition, unless medical contraindica- 
tions existed, we attempted to perform predischarge angiog- 
raphy in all asymptomatic patients. 
Follow-up. Long-term data were collected from clinic 
and telephone interviews, questionnaires and discussions 
with referring physicians. This information was stored in a 
computer data base and updated periodically. The New 
York Heart Association functional classification of angina 
pectoris (18) was recorded at the time of latest follow-up 
evaluation. 
Data analysis. Left ventricular end-systolic and end- 
diastolic frames were digitized from the left ventriculogram 
and stored in a Tektronix 4052 computer; ejection fraction 
was calculated with a modification of the Dodge area-length 
method (19). Regional wall motion was determined by a 
modification of the centerline chord method, dividing the left 
ventricle into 19 regions (20). Improved regional wall motion 
was defined as an increase in regional wall motion score by 
~1 SD in at least one segment within the infarct zone and 
positive improvement in at least half of the remaining 
segments within the infarct zone. With use of visual im- 
provement in regional wall motion as the reference standard, 
this definition has been shown in our laboratory to have the 
highest sensitivity and specificity of five different sets of 
criteria tested in a double-blind fashion. 
Statistics. Fisher’s exact test or chi-square analysis was 
used for comparisons between categorical variables. The 
two-tailed Student’s t test was used for comparisons be- 
tween continuous variables. Survival curves were generated 
using the Kaplan-Meier method. Multivariate analysis of 
survival events was performed with Cox proportional hazard 
regression. Stepwise logistic regression analysis was used to 
examine predictors of improvement of left ventricular func- 
tion. A p value ~0.05 was considered significant. 
Results 
Baseline clinical characteristics. These are summarized in 
Table 1, and the data derived from acute coronary angiog- 
raphy in Table 2. The mean time from symptom onset to 
angioplasty was 5 h; 60% of patients underwent angioplasty 
within 4 h and 85% within 6 h. Patients undergoing angio- 
plasty after 6 h either had significant ongoing ischemic pain 
or presented with a “stuttering” course. The infarct-related 
artery was totally occluded in 127 patients (59%), 95% to 
99% stenotic in 80 patients (37%) and 75% to 94% stenotic in 
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Table 1. Baseline Clinical Characteristics of 215 Patients 
Age (yr) 
Mean 2 SD 
Range 
265 years 
Gender 
Male 
Female 
Prior bypass surgery 
Cardiogenic shock 
Time (min) (mean 2 SD)* 
Oto2h 
2to4h 
4to6h 
6 to 24 h 
*From symptom onset to coronary angioplasty. 
56r 11 
30 - 83 
54 (25%) 
161 (75%) 
54 (25%) 
4 (2%) 
6 (3%) 
299 t 240 
31 (14%) 
98 (46%) 
53 (25%) 
33 (15%) 
8 patients (4%); angiographic evidence of thrombus was 
usually present in subtotally occluded arteries. Ejection 
fraction was depressed (<50%) in 62 patients (29%). 
Results of acute angioplasty. Coronary angioplasty was 
successful in 212 (99%) of the 215 patients. There were no 
deaths during the initial procedure. Complications consisted 
of a single urgent coronary bypass operation (0.5%) after a 
failed angioplasty. Angioplasty was successful in 125 (98%) 
of 127 patients with a totally occluded infarct-related artery 
and 87 (99%) of 88 patients with a subtotally occluded 
infarct-related artery (p = 0.98). 
Hospital course (Table 3). Three patients (1%) died before 
discharge. One patient developed ventricular fibrillation 6 
days after successful dilation of the proximal left anterior 
descending artery. Angiography after defibrillation showed 
total occlusion at the original site with thrombus present. 
Sustained patency of the infarct-related artery could not be 
achieved, and refractory ventricular arrhythmias developed, 
resulting in death. The second patient died of progressive 
biventricular failure 2 weeks after successful dilation of the 
proximal right coronary artery. The third patient developed 
acute anterior infarction 3 days after admission for sepsis 
related to long-term ambulatory peritoneal dialysis; patency 
of the occluded proximal left anterior descending artery was 
rapidly restored. She died 2 weeks later of septic shock. 
Before discharge, eight patients (4%) had a recurrent 
ischemic event, which was usually managed successfully 
with repeat angioplasty (Table 3). Acute reocclusion of the 
infarct-related vessel was responsible for five of these 
events. In addition, unsuspected reocclusion was found in 9 
(7%) of 121 asymptomatic patients who underwent routine 
predischarge angiography. Thus, the angiographic reocclu- 
sion rate was 11% (14 of 126), and reocclusion was asymp- 
tomatic in 64% of these patients. Repeat coronary angio- 
plasty was performed in 12 patients (6%) before discharge, 
successfully in 11 (92%). 
Left ventricular function. Predischarge angiography was 
available in 126 patients (59%). The only significant baseline 
difference in clinical and angiographic variables between 
patients with and without follow-up angiography (Table 4) 
was a higher incidence of collateral vessels in the former 
group (26% versus 13%, p = 0.04). 
The left ventricular ejection fraction increased from 55% 
? 12% to 61% ? 12% (p < 0.005) and increased ~5% units 
in 66 patients (52%). The gain in ejection fraction was 
equivalent in those with anterior and inferior infarction (Fig. 
1). From 15 clinical and angiographic variables, univariate 
and multivariate analysis identified only a depressed initial 
ejection fraction and young age as independent predictors of 
serial improvement in ejection fraction before discharge 
(Table 5). The ejection fraction increased from 42% ? 6% to 
57% ? 13% in the 39 patients with an initial ejection fraction 
~50% (p < O.OOS), but was unchanged in the 87 patients with 
an initial ejection fraction ~50% (61% t 8% to 63% + 12%, 
p = 0.14). Paired ventriculograms were available in four 
patients who presented with cardiogenic shock. In this 
group, the ejection fraction increased from 23% 2 5% to 
49% ? 7% (p < 0.005). 
Regional wall motion improved in 60 patients (48%). A 
depressed initial ejection fraction, limited increase in creat- 
ine kinase and sustained patency of the infarct-related artery 
independently correlated with improvement in regional wall 
motion (Table 5, Fig. 2 and 3). 
Late morbidity and mortality (Table 6). Follow-up data 
were available in 214 patients (99.5%) at a mean interval of 
35 -+ 19 months. There were 17 late deaths, 5 of which were 
noncardiac. The actuarial 3 year survival rate (including 
in-hospital mortality) and cardiac survival rate were 90% and 
92%, respectively (Fig. 4). 
After discharge, the annual mortality rate was 2%. Cox 
Table 2. Initial Angiographic Findings in 215 Patients 
Infarct-related artery 
LAD 91 (42%) 
Proximal LAD 72 (33%) 
Mid/distal LAD 19 (9%) 
Left circumflex artery 27 (13%) 
Right coronary artery 94 (44%) 
Saphenous vein graft 3 (1%) 
Infarct location 
Anterior 94 (44%) 
Inferior 121 (56%) 
TIMI coronary flow grade 
TIMI 0 128 (60%) 
TIM1 I 48 (22%) 
TIM1 II 39 (18%) 
Collateral vessels present 45 (21%) 
Thrombus present 134 (62%) 
Ejection fraction (mean + SD) 54% + 12% 
LAD = left anterior descending coronary coronary artery; TIM1 = 
thrombolysis in Myocardial Infarction. 
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Table 3. In-Hospital Events in 215 Patients -_---- ___._ ___, _. - -_.. -___i_-~l_l.~-.- 
Event During PTCA After PTCA Total 
I_.--_ _ -.--- ____“_~~ _ _... - ___-.- ._-.-. -. ..-_____- 
Death 0 3 3 (1%) 
Bypass surgery I I 2 (1%) 
Repeat IXA 0 II 12 (6%) 
___ .___ ___ .-- -.. _ ..- ---. 
Recurrent Ischemlc 
Events After 
PTCA Therapy/Outcome 
I__._____---- __-_._--.. ---_-~--~ “.-_I ---- --- 
Exertionai angina I (1%) Successful repeat angiopiasty in I 
Rest angina 4 (2%) Successful repeat angiopiasty in 4 
Cardiac arrest 3 (1%)’ Bypass surgery in 1: death m 2 
Total 8 (4%) 
____--__l__-- “___ ., __________ .__ ._ _ _I ______~..__ _.-_ -_ .,. 
*Reinfarction developed in two (1%) of these patients. 
regression analysis identified depressed initial ejection frac- 
tion as the sole independent covariate of cardiac death 
(Table 7). Only two of the six patients who presented with 
cardiogenic shock died (one patient before discharge and one 
patient 14 months after discharge). 
Nine patients (4%) sustained a late nonfatal myocardial 
infarction, and 11 patients (5%) underwent late coronary 
bypass surgery. Considering cardiac death, nonfatal infarc- 
tion and bypass surgery as events, the actuarial 3 year 
event-free survival rate was 84% (Fig. 4). Only anterior 
infarct location was found to be independently associated 
with late cardiac events (Table 7). 
Sixty-nine repeat coronary angioplasty procedures were 
performed after discharge in 52 patients (24%); repeat 
angioplasty was first performed >8 months after the acute 
infarct procedure in 26 (50%) of these 52 patients. At late 
follow-up evaluation, 149 (77%) of 194 patients alive were 
asymptomatic and 29 patients (15%) had only mild angina. 
Table 4. Baseline Characteristics of 215 Patients With and 
Without Predischarge Angiography 
No 
Predischarge Predischarge 
Angiography Angiography 
(n 1 126) (n = 89) p Value 
-- - _--. _- -..- ___I_ 
Male (%) 75 74 NS 
Age (~0 56 t Ii 57 + II NS 
Prior bypass (%) 2 2 NS 
Shock (%) 2 3 NS 
Anterior MI (%) 39 51 NS 
Initial EF (%) 55% + 12% 43% + 12% NS 
Collateral vessels (%) 26 13 0.04 
Thrombus (%) 63 62 NS 
Time to angiopiasty (min) 292 + 209 307 ? 279 NS 
Angioplasty success (SC) 100 97 NS 
Peak CK 1.913 r 1.702 1.658 * 1,669 EUS 
-_-- 
CK = serum creatine kinase; EF = ejection fraction: MI = myocardiai 
infarction: PTCA = percutaneous transiuminal coronary angiopiasty. 
Discussion 
Natural history of patients with single vessel coronary 
artery disease after acute myocardial infarction. Though the 
number of diseased epicardial coronary arteries has been 
shown to be an important determinant of short- and long- 
term prognosis after acute myocardial infarction (1 l-14), 
limited data exist regarding the natural history of patients 
with single vessel coronary disease after myocardial infarc- 
tion. I’he 3 year survival rate in patients ~60 to 65 years old 
with single vessel disease after uncomplicated myocardial 
infarction has been consistently >90% (11-14). However, 
7% to 16% of these patients may develop reinfarction during 
the same period (13,14). Wilson et al. (15) followed up 97 
patients with single vessel disease treated with conventional 
therapy after uncomplicated myocardlal infarction. Al- 
though there were no deaths and only six cases of reinfarc- 
tion (6%) over a 39 month follow-up period, 56% of patients 
developed angina and 26% of patients required repeat hos- 
pitalization for functional class III or IV angina. Revascu- 
larization was required in 10% of patients. Advanced age, 
Figure 1. Improvement in ejection fraction after direct coronary 
angioplasty in 126 patients. MI = myocardial infarction. 
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Table 5. Predictors of Improvement in Ejection Fraction and 
Regional Wall Motion After Direct Angioplasty 
Univariate Multivariate 
Analysis Analysis 
(p value) (p value) 
Ejection fraction improvement 9% 
Low initial EF 0.001 0.001 
Young age 0.02 0.015 
Patent infarct-related artery 0.14 NS 
Determinants of regional wall motion improvement 
Limited CK increase 0.03 0.004 
Low initial EF 0.001 0.008 
Patent infarct-related artery 0.08 0.087 
Variables not significantly associated with improved left ventricular 
function included gender, prior bypass surgery, time to angioplasty, stenosis 
severity, collateral circulation, thrombus and location of infarction. Abbrevi- 
ations as in Table 4. 
female gender, cardiogenic shock and depressed left ventric- 
ular function have been found to be powerful determinants 
of both in-hospital and long-term mortality after acute reper- 
fusion in patients with single vessel disease (21-23). How- 
ever, the optimal therapy for patients with an evolving 
myocardial infarction and single vessel disease is unknown. 
Outcome After Direct Coronary Angioplasty: 
Results of the Present Study 
Patient selection and efficacy of reperfusion. At our insti- 
tution, >97% of all patients presenting with acute myocar- 
dial infarction are taken to the catheterization laboratory 
without prior administration of thrombolytic therapy, and 
angioplasty is performed when appropriate. High risk pa- 
tients, including the elderly and those with prior coronary 
bypass surgery or cardiogenic shock, are not excluded. 
Single vessel disease was present in 43% of our patients, 
consistent with data from other series (11-14). Twenty-five 
percent of these patients were >65 years old, and 29% had 
global left ventricular dysfunction (ejection fraction ~50%). 
Despite the inclusion of high risk patients, the very high 
patency rate achieved with direct coronary angioplasty 
(99%), with few complications (0.5% bypass surgery and no 
procedural mortality), compares favorably with the results 
seen with other forms of reperfusion therapy (l-5,9,21,24). 
In-hospital course. After direct angioplasty, only 1% of 
patients died during the hospitalization. Five (87%) of six 
patients presenting with cardiogenic shock were alive at 
discharge. Recurrent ischemic events before discharge were 
rare (4%) and were usually treated effectively with repeat 
coronary angioplasty. In-hospital coronary reocclusion was 
observed in only 11% of patients undergoing predischarge 
angiography. Prompt restoration of Thrombolysis in Myo- 
cardial Infarction (TIMI) grade III flow, aggressive antico- 
agulation with heparin and aspirin and assurance of hemo- 
dynamic stability may in part have contributed to the low 
rate of in-hospital mortality and vessel closure. Of note, 
reocclusion was asymptomatic in the majority of cases, 
suggesting either significant collateral vessel development, 
completed infarction or the presence of true “silent” isch- 
emia or reinfarction. 
An aggressive approach to ensure continued vessel pa- 
tency was maintained throughout the hospitalization. Thus, 
93% of our patients who underwent predischarge angiogra- 
phy were discharged with a patent infarct-related artery. 
Sustained vessel patency has been shown to be an important 
determinant of recovery of left ventricular iunction 
(21,22,25). Additionally, establishment of an open infarct- 
related artery may prevent ventricular aneurysm formation 
(26), raise the threshold for induction of ventricular tachy- 
cardia (27) and result in improved long-term survival inde- 
pendent of myocardial salvage (28). 
Myocardial salvage. Despite disease limited to one coro- 
nary artery, left ventricular ejection fraction and regional 
wall motion improved significantly in 50% of patients by the 
time of hospital discharge. In concert with data from other 
studies (21,22,25), the most powerful predictors of improved 
left ventricular function were a depressed ejection fraction 
before angioplasty and sustained patency of the infarct- 
related artery. Regional wall motion also improved signifi- 
cantly in patients with a limited increase in creatine kinase, 
consistent with enhanced myocardial salvage. Alternatively, 
reversible ischemia in the infarct zone at presentation may 
explain the marked improvement in regional wall motion in 
patients with a low initial ejection fraction but subsequent 
limited increase in creatine kinase. As in recent reports 
(21,25,29,30), the time to reperfusion was not strongly asso- 
ciated with myocardial salvage, emphasizing the importance 
of collateral circulation, as well as the dynamic nature of 
coronary obstruction. 
Long-term morbidity and mortality. Previous studies (1 l- 
14) have demonstrated a 90% to 99% 3 year survival rate 
after uncomplicated infarction in patients with single vessel 
disease. However, these reports generally excluded elderly 
patients and high risk subsets. Thus, the 94% 3 year survival 
rate after direct angioplasty and hospital discharge in our 
patient cohort, which included elderly patients, those in 
shock and those with in-hospital complications, suggests a 
favorable effect on long-term mortality. Multivariate analy- 
sis identified only depressed initial ejection fraction as pre- 
dictive of cardiac mortality. As reported by Stack et al. (23), 
the time to reperfusion was not an independent predictor of 
long-term mortality. Advanced age was not predictive of 
cardiac mortality in patients with single vessel disease. 
Despite this relatively high risk cohort of patients, the 4% 
incidence rate of late infarction and 5% incidence rate of late 
coronary bypass surgery also compare favorably with low 
risk historical control subjects (13-E). In addition, at 3 year 
follow-up evaluation, 77% of our patients were asymptom- 
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Figure 2. Improvement in regional wall motion (segmental EF) after 
direct coronary angioplasty, demonstrating the influence of baseline 
ejection fraction (EF). PTCA = percutaneous transluminal coronary 
angioplasty. 
atic and only 8% had class III or IV angina. Repeat angio- 
plasty was required after discharge in 24% of our patients. 
The occurrence of a late cardiac event (>I year after 
discharge), along with the observation that 12% of our 
patients required repeat coronary angioplasty >8 months 
after the initial dilation, suggests that progression of athero- 
sclerotic disease may contribute to late morbidity and mor- 
tality in patients with single vessel disease after acute 
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myocardial infarction. Thus, an aggressive strategy of revas- 
cularization may be necessary to ensure angina-free and 
infarct-free late survival after initial reperfusion. 
Comparison with thromholytic therapy. Several theoreti- 
cal and practical considerations limit the ultimate effective- 
ness of thrombolytic therapy. There appears to be a phar- 
macologic plateau of coronary thrombolytic efficacy of 
approximately 70% to 80% (21). There currently is no rapid, 
accurate means to noninvasively detect reperfusion at the 
bedside (31). In addition to the 99% reperfusion rate in the 
present study, the 4% incidence rate of recurrent in-hospital 
ischemic events and 11% incidence rate of angiographic 
reocclusion after direct coronary angioplasty compare favor- 
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ably with the 20% to 30% incidence rate of recurrent 
ischemic events and reocclusion after thrombolytic therapy 
(2,8,29,32-34). 
Myocardial salvage and late survival have not been 
specifically reported in patients with single vessel disease 
after thrombolytic therapy. However, direct angioplasty has 
been associated with greater improvement in ventricular 
function than after thrombolysis alone (8,9,25); the only two 
randomized trials (29,35) of thrombolytic therapy versus 
direct angioplasty found improved global and regional left 
ventricular function and less exercise-induced ischemia as- 
sociated with less severe residual coronary stenosis in the 
patients treated with angioplasty. The 5% to 8% annual 
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Figure 3. Improvement in regional wall motion (segmental EF) after 
direct coronary angioplasty, demonstrating the influence of sus- 
tained patency of the infarct-related artery. 
mortality rate observed after thrombolytic therapy appears 
to be higher than the 1% to 3% yearly mortality rate after 
direct angioplasty (8,23,25,36). The 70% to 85% mortality 
rate in patients with cardiogenic shock treated convention- 
ally or with thrombolytic therapy (1,37-39) may be reduced 
to 35% to 45% with angioplasty (40,41). In the present series, 
five (87%) of six patients with single vessel disease and 
cardiogenic shock were discharged alive. 
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Table 6. Long-Term Morbidity and Mortality After Direct 
Angioplasty in 214 Patients (mean follow-up 35 months) 
Out of 
Event In-Hospital Hospital Total 
Death 3 (1%) 17 (8%) 20 (9%) 
Cardiac death 3 (1%) 12 (6%) 15 (7%) 
Nonfatal MI I (1%) 9 (4%) IO (5%) 
Bypass surgery 2 (1%) 1 I (5%) 13 (6%) 
Cardiac events* 5 (2%) 29 (14%) 34 (16%) 
Repeat angioplasty 12 (6%) 52 (24%) 57 (27%) 
New York Heart Association classification 
(in 194 patients alive) 
Ck+SS i 149 (77%) 
Class II 29 (15%) 
Class III 8 (4%) 
Class IV 8 (4%) 
*Cardiac death, myocardial infarction or bypass surgery; 1 patient with 
in-hospital myocardial infarction and 3 patients with late myocardial infarction 
also under went bypass surgery; 7 patients had repeat angioplasty both before 
and after discharge. Abbreviations as in Table 4. 
With current doses, thrombolytic therapy is associated 
with an 8% to 12% incidence rate of significant bleeding and 
a 0.5% risk of intracranial hemorrhage (8,42,43). The risk of 
major bleeding when coronary angioplasty is performed 
alone is ~2%; bleeding most commonly occurs at the cath- 
eterization site and is usually minor; intracranial hemorrhage 
is extremely rare (8,42). Finally, with current eligibility 
criteria, only 14% to 43% of patients presenting with acute 
myocardial infarction are candidates for thrombolytic ther- 
apy (21,42). 
Limitations. Although this study consists of a consecu- 
tive series of patients with acute myocardial infarction and 
single vessel disease, it is uncontrolled and retrospective in 
nature and reflects the clinical experience of a single group of 
experienced interventional cardiologists. Firm conclusions 
comparing direct angioplasty with other modes of reperfu- 
Table 7. Predictors of Morbidity and Mortality in 214 Patients 
After Direct Angioplasty 
Univariate Multivariate 
Analysis Analysis 
(p value) (p value) 
Cardiac mortality 
Low initial EF 0.007 0.012 
Shock 0.08 NS 
Cardiac events* 
Anterior MI 0.09 0.018 
Shock 0.05 NS 
Closed infarct-related artery 0.09 NS 
*Cardiac death, myocardial infarction or bypass surgery. Variables not 
significantly associated with survival included gender, prior bypass surgery, 
time to angioplasty, stenosis severity, collateral circulation, thrombus and 
peak creatine kinase. Abbreviations as in Tables 4 and 5. 
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Figure 4. Long-term morbidity and mortality in 214 patients after 
direct coronary angioplasty. 
sion will require controlled randomized studies and should 
include a detailed cost-benefit analysis. 
Despite the goal of predischarge angiography in all pa- 
tients, paired ventriculography was available in only 59% of 
patients. Although the baseline clinical and angiographic 
characteristics were similar in the two groups (Table 4), 
selection bias may nonetheless have occurred. In addition, 
multivariate analysis may have identified other covariates of 
myocardial salvage and survival had greater numbers of 
patients been available. 
Practical considerations. Because only 12% of centers in 
the United States have facilities for coronary angioplasty 
(44), direct angioplasty is not feasible for the majority of 
patients with acute myocardial infarction. In addition, this 
approach requires around the clock availability of an inter- 
ventional cardiologist and catheterization team skilled in 
acute infarct angioplasty and committed to rapid mobiliza- 
tion, conditions that are logistically and financially impossi- 
ble to meet at many institutions. However, in centers so 
equipped, direct angioplasty in evolving myocardial infarc- 
tion may be performed expeditiously and result in a low 
in-hospital mortality rate, dramatic improvement in left 
ventricular function and extended long-term survival (8,25). 
In addition, direct coronary angioplasty is the optimal treat- 
ment for the 57% to 86% of patients not eligible for throm- 
bolytic therapy (21,42). 
Conclusions. In patients with single vessel coronary ar- 
tery disease and evolving acute myocardial infarction, direct 
coronary angioplasty without prior thrombolytic therapy can 
be performed with a very high success rate and few proce- 
dural complications. Regional wall motion and ejection 
fraction improve in 50% of patients, especially in those with 
depressed ventricular function. This approach results in 
excellent early and late event-free survival and improved 
symptomatic status and compares favorably with results 
reported with conventional therapy or thrombolytic reperfu- 
sion. 
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